Pemafibrate, a new and specific modulator of PPARα, has demonstrated advantageous effects on liver histology and liver enzymes in both preclinical NAFLD models and in individuals with diabetes and dyslipidemia81. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.